. . "The reason why the Duty is necessary for the Responsible_party. Rigorous posttreatment follow-up is mandatory, because long-term recurrence rates after treatment of melanoma in situ with imiquimod are yet unknown."@en . . . "8147"^^ . . . "2005-06-10T12:07:02+02:00"^^ . "Explanation" . "exp" .